← Back to Search

Cholinergic Agonist and Alpha-2 Adrenergic Agonist

Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally for Presbyopia

Phase 2
Waitlist Available
Research Sponsored by LENZ Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour post treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial tests two types of eye drops to help people with Presbyopia read better by improving their near vision. One drop combines two drugs, while the other uses just one. The combination of pilocarpine and oxymetazoline has been studied for its safety and effectiveness in treating presbyopia.

Eligible Conditions
  • Presbyopia
  • Refractive Errors
  • Eye Diseases
  • None

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Vehicle Ophthalmic Solution dosed bilaterallyExperimental Treatment3 Interventions
Proprietary Vehicle ophthalmic solution
Group II: Combination ophthalmic solution (LNZ101) dosed bilaterallyExperimental Treatment3 Interventions
LNZ101: Aceclidine/Brimonidine combination ophthalmic solution
Group III: Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterallyExperimental Treatment3 Interventions
LNZ100: Aceclidine ophthalmic solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aceclidine ophthalmic solution
2022
Completed Phase 2
~130
Aceclidine+Brimonidine combination ophthalmic solution
2023
Completed Phase 3
~720
Vehicle Proprietary Ophthalmic Solution
2022
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,891 Total Patients Enrolled
5 Trials studying Presbyopia
1,148 Patients Enrolled for Presbyopia
LENZ Therapeutics, IncLead Sponsor
9 Previous Clinical Trials
1,547 Total Patients Enrolled
9 Trials studying Presbyopia
1,547 Patients Enrolled for Presbyopia
Alisyn Facemire, BAStudy DirectorLENZ Therapeutics, Inc
4 Previous Clinical Trials
1,118 Total Patients Enrolled
4 Trials studying Presbyopia
1,118 Patients Enrolled for Presbyopia
~19 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top